Alpine Associates Management Inc. Cerevel Therapeutics Holdings, Inc. Transaction History
Alpine Associates Management Inc.
- $2.56 Billion
- Q1 2024
A detailed history of Alpine Associates Management Inc. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Alpine Associates Management Inc. holds 2,341,394 shares of CERE stock, worth $95.7 Million. This represents 3.86% of its overall portfolio holdings.
Number of Shares
2,341,394
Previous 1,644,100
42.41%
Holding current value
$95.7 Million
Previous $69.7 Million
41.98%
% of portfolio
3.86%
Previous 3.67%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.69 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$441 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$309 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$305 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$223 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.37B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...